TITLE:
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)

CONDITION:
Melanoma

INTERVENTION:
Temozolomide

SUMMARY:

      The purpose of this study is to ascertain if the extended schedule of Temozolomide, which
      allows increased doses and potential depletion of the enzyme underlaying resistance, is a
      more effective treatment of metastatic melanoma than single agent dacarbazine.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Histologically confirmed, stage IV, surgically incurable melanoma

          -  Age 18 years or older

          -  World Health Organization (WHO) Eastern Cooperative Oncology Group (ECOG) performance
             status of 0 or 1

          -  Meets protocol requirements for specified laboratory values

          -  Must be able to take oral medication

          -  Must be disease free from cancer for period of 5 years (except for surgically cured
             carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin).

          -  Women of childbearing potential and men must be practicing a medically approved
             contraception.

          -  Must provide written informed-consent to participate in the study.

          -  Must have full recovery from major surgery or adjuvant treatment

          -  No clinically uncontrolled infectious disease including HIV or AIDS-related illness

        Exclusion Criteria:

          -  Ocular melanomas

          -  Brain Metastases

          -  Prior cytokine or chemotherapy for stage IV disease

          -  Pregnant or nursing women
      
